New SAB member brings rich experience and expertise in liver disease, pharma drug development as well as a keen interest in 3D in vitro technologies
Schlieren, Switzerland – February 9, 2022 InSphero AG, the pioneer in 3D cell-based assay and organ-on-chip technology, today announced the strengthening of its Scientific Advisory Board (SAB) with the appointment of Professor Nikolai Naoumov, MD PhD. “We are pleased to welcome this distinguished researcher to our SAB,” says InSphero VP Francisco Verdeguer, PhD. “Nikolai’s diverse expertise in liver diseases will provide invaluable insight as we continuously advance our tailored drug development efforts at the forefront of preclinical NASH research. Visionary science has always been a driving force for InSphero’s advanced and screenable spheroid models in drug discovery and safety. Nikolai will not only guide us but also serve as a sounding board to challenge us and bring added value to our collaborative research partnerships with leading pharma and biotech organizations.”
Prof. Naoumov is a is distinguished physician-scientist, with a professional career spanning academia, clinical care, and drug development. He is a Fellow of both the Royal College of Physicians (London) and the Royal College of Pathologists (UK). His research has integrated immunology, molecular biology, and translational medicine in elucidating virus-host interactions and mechanisms of liver injury. Nikolai has led research teams at the Medical Academy Sofia, King’s College Institute of Liver Studies in London, and subsequently as Professor of Hepatology at University College London. Most recently, Prof. Naoumov expanded his contributions to medical science and clinical hepatology as Global Head, Therapeutic Area Hepatology, and Transplantation at Novartis. In parallel, he continued contributing to liver research and education as Honorary Professor of Hepatology at UCL, Scientific Advisor to the Foundation for Liver Research in the UK, and a board member of the Liver Foundation in Switzerland.
Professor Naoumov says, “NASH is a complex disease with pathobiology involving multiple pathways and heterogenous patient population. The pathogenesis of NASH is not fully understood, and no therapies have yet been approved. In part, this is due to a lack of reliable and predictive preclinical models. I am excited for the opportunity to guide the NASH model development with an innovative company such as InSphero.”
For more information about InSphero Leadership, visit https://insphero.com/leadership.
# # # #
InSphero is the pioneer of industrial-grade, 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology. Through partnerships, InSphero supports pharmaceutical and biotechnology researchers in successful decision-making by accurately rebuilding the human physiology in vitro. Its robust and precisely engineered suite of 3D InSight™ human tissue platforms are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. The company specializes in liver toxicology, metabolic diseases (e.g., T1 & T2 diabetes and NAFLD & NASH liver disease), and oncology (with a focus on immuno-oncology and PDX models). The scalable Akura™ technology underlying the company’s 3D InSight™ Discovery and Safety Platforms includes 96 and 384-well plate formats and the Akura™ Flow organ-on-a-chip system to drive efficient innovation throughout all phases of drug development.
Dr. Frank Junker
InSphero Chief Business Officer
Phone +41 44 5150490